CDXC logo

Niagen Bioscience, Inc. (CDXC)

Profile

Full Name

Niagen Bioscience, Inc.

Ticker

NASDAQ: CDXC

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 25, 2008

Indexes

Not included

Website

https://www.chromadex.com

Employees

104

Key Details

Price

-

Market cap

-

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$99.60M(+19.18% YoY)

Annual EPS

$0.11(+257.14% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    -
    CDXC price value is unknown

    30-Day Relative Volume

    -
    CDXC 30-day relative volume value is unknown

    Price Performance

    Price Most recent change

    -
    CDXC price change on Jan 1, 1 is unknown

    Price YTD change

    -
    CDXC price ytd change is unknown

    Price 1-year change

    -
    CDXC price 1-year change is unknown

    Price 3-year change

    -
    CDXC price 3-year change is unknown

    Price Range

    Price All-time high

    $23.66
    CDXC price is currently at an all-time high

    Price 3-year low

    $1.15
    CDXC price is currently at its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market cap

    -
    CDXC market capitalization value is unknown

    Market cap 3-year change

    -
    CDXC market capitalization 3-year change is unknown

    Market cap All-time high

    $1.24B
    CDXC market capitalization is currently at an all-time high

    Market cap sector rank

    -
    CDXC market capitalization is unknown

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +2.39%
    CDXC shares outstanding is up +2.39% year-on-year

    Shares Outstanding 3-Year Change

    +13.77%
    CDXC shares outstanding is up +13.77% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    -
    CDXC beta value is unknown

    200-day SMA

    -
    CDXC SMA 200 is unknown

    50-day SMA

    -
    CDXC SMA 50 is unknown

    RSI

    -
    CDXC 14-day relative strength index value is unknown

    Volume

    -
    CDXC 30-day relative volume value is unknown

    ATR

    -
    CDXC average true range value is unknown

    10-day Historical Volatility

    -
    CDXC 10-day historical volatility value is unknown

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $99.60M
    CDXC annual revenue is $99.60 million

    Revenue Analysts estimate

    $118.50M
    CDXC annual revenue is currently -15.95% lower than the consensus analysts' forecast

    Revenue 1-year change

    +19.18%
    CDXC annual revenue is up +19.18% year-on-year

    Revenue Sector rank

    -
    CDXC annual revenue is unknown

    EPS

    EPS

    $0.11
    CDXC annual earnings per share is $0.11

    EPS Analysts estimate

    $0.12
    CDXC annual earnings per share is currently -5.74% lower than the consensus analysts' forecast

    EPS 1-year change

    +257.14%
    CDXC annual earnings per share is up +257.14% year-on-year

    EPS Sector rank

    -
    CDXC annual earnings per share is unknown

    Profit

    Gross profit

    $61.59M
    CDXC annual gross profit is $61.59 million

    Gross margin

    61.84%
    CDXC annual gross profit margin is 61.84%

    Operating profit

    $7.73M
    CDXC annual operating income is $7.73 million

    Operating margin

    7.76%
    CDXC annual operating profit margin is 7.76%

    Net income

    $8.55M
    CDXC annual net profit is $8.55 million

    Net margin

    8.58%
    CDXC annual net profit margin is 8.58%

    Expenses

    Total expenses

    $91.87M
    CDXC annual total expenses is $91.87 million

    Operating expenses

    $53.86M
    CDXC annual total operating expenses is $53.86 million

    Cost of goods sold

    $38.01M
    CDXC annual cost of goods sold is $38.01 million

    Selling, general & administrative expenses

    $47.84M
    CDXC annual SGA is $47.84 million

    Depreciation and amortization

    $1.48M
    CDXC annual depreciation & amortization is $1.48 million

    Interest expense

    -
    CDXC annual interest expense value is unknown

    Income tax

    $305.00K
    CDXC annual income tax is $305.00 thousand

    EBIT & EBITDA

    EBIT

    $7.73M
    CDXC annual earnings before interest & taxes is $7.73 million

    EBITDA

    $9.21M
    CDXC annual EBITDA is $9.21 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total assets

    $68.28M
    CDXC annual total assets is $68.28 million

    Non current assets

    $4.18M
    CDXC annual long term assets is $4.18 million

    Current assets

    $64.10M
    CDXC annual total current assets is $64.10 million

    Cash and cash equivalents

    $44.51M
    CDXC annual cash & cash equivalents is $44.51 million

    Accounts receivable

    $7.77M
    CDXC annual accounts receivable is $7.77 million

    Inventory

    $9.19M
    CDXC annual inventory is $9.19 million

    Liabilities

    Total liabilities

    $22.18M
    CDXC annual total liabilities is $22.18 million

    Long term liabilities

    $4.24M
    CDXC annual total long term liabilities is $4.24 million

    Current liabilities

    $17.95M
    CDXC annual total current liabilities is $17.95 million

    Accounts payable

    $8.53M
    CDXC annual accounts payable is $8.53 million

    Debt

    Total debt

    $2.65M
    CDXC annual total debt is $2.65 million

    Total debt 1-year change

    -19.1%
    CDXC annual total debt is down -19.1% year-on-year

    Long term debt

    $1.66M
    CDXC annual long term debt is $1.66 million

    Short term debt

    $994.00K
    CDXC annual short term debt is $994.00 thousand

    Equity & Capital

    Shareholders equity

    $46.09M
    CDXC annual stockholders equity is $46.09 million

    Book value

    $46.09M
    CDXC annual book value is $46.09 million

    Retained earnings

    -$181.91M
    CDXC annual retained earnings is -$181.91 million

    Working capital

    $46.15M
    CDXC annual working capital is $46.15 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash from operations

    $12.11M
    CDXC annual cash flow from operations is $12.11 million

    Cash from operations 1-year change

    +70.14%
    CDXC annual cash flow from operations is up +70.14% year-on-year

    Cash from investing

    -$143.00K
    CDXC annual cash flow from investing activities is -$143.00 thousand

    Cash from investing 1-year change

    0%
    CDXC annual cash flow from investing activities has remained unchanged year-on-year

    Cash from financing

    $5.37M
    CDXC annual cash flow from financing activities is $5.37 million

    Cash from financing 1-year change

    +6065.56%
    CDXC annual cash flow from financing activities is up +6065.56% year-on-year

    CAPEX

    CAPEX

    $163.00K
    CDXC annual capital expenditures is $163.00 thousand

    CAPEX 1-year change

    +10.14%
    CDXC annual capital expenditures is up +10.14% year-on-year

    Free Cash Flow

    Free cash flow

    $11.95M
    CDXC annual free cash flow is $11.95 million

    Free cash flow 1-year change

    +71.42%
    CDXC annual free cash flow is up +71.42% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross margin

    61.84%
    CDXC annual gross profit margin is 61.84%

    Operating margin

    7.76%
    CDXC annual operating profit margin is 7.76%

    Net margin

    8.58%
    CDXC annual net profit margin is 8.58%

    ROA & ROE

    ROA

    13.88%
    CDXC annual return on assets is 13.88%

    ROE

    22.94%
    CDXC annual return on equity is 22.94%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE ratio

    -
    CDXC price to earnings ratio value is unknown

    PE ratio Sector rank

    -
    CDXC price to earnings ratio is unknown

    PB Ratio

    PB ratio

    -
    CDXC price to book ratio value is unknown

    PB ratio Sector rank

    -
    CDXC price to book ratio is unknown

    PS Ratio

    PS ratio

    -
    CDXC price to sales ratio value is unknown

    PS ratio Sector rank

    -
    CDXC price to sales ratio is unknown

    Enterprise value

    Enterprise value

    -
    CDXC enterprise value value is unknown

    Enterprise value Sector rank

    -
    CDXC enterprise value is unknown

    EV/EBITDA

    EV/EBITDA

    -
    CDXC EV/EBITDA value is unknown

    EV/EBITDA Sector rank

    -
    CDXC EV/EBITDA is unknown

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current ratio

    3.57
    CDXC annual current ratio is 3.57

    Quick ratio

    3.06
    CDXC annual quick ratio is 3.06

    Leverage

    Debt to equity

    0.00
    CDXC annual debt to equity ratio is 0.00

    Interest coverage ratio

    -
    CDXC annual interest coverage ratio value is unknown

    Risk & Stability

    Piotroski F-Score

    7
    CDXC piotroski f-score is 7

    Altman Z-Score

    -
    CDXC altman z-score value is unknown

    Analyst ratings

    Recent major analysts updates

    Apr 8, 25 HC Wainwright & Co.
    Buy
    Mar 31, 25 HC Wainwright & Co.
    Buy
    Mar 17, 25 HC Wainwright & Co.
    Buy
    Mar 10, 25 HC Wainwright & Co.
    Buy
    Mar 5, 25 Ladenburg Thalmann
    Buy
    Nov 6, 24 Roth MKM
    Buy
    Nov 4, 24 HC Wainwright & Co.
    Buy
    Aug 9, 24 HC Wainwright & Co.
    Buy
    Jul 15, 24 HC Wainwright & Co.
    Buy
    Jun 12, 24 Roth MKM
    Buy

    Institutional Ownership

    Screeners with CDXC included

    Stocks above SMA 50
    • What is the ticker symbol for Niagen Bioscience, Inc.?
    • Does Niagen Bioscience, Inc. pay dividends?
    • What sector is Niagen Bioscience, Inc. in?
    • What industry is Niagen Bioscience, Inc. in?
    • What country is Niagen Bioscience, Inc. based in?
    • When did Niagen Bioscience, Inc. go public?
    • Is Niagen Bioscience, Inc. in the S&P 500?
    • Is Niagen Bioscience, Inc. in the NASDAQ 100?
    • Is Niagen Bioscience, Inc. in the Dow Jones?
    • When was Niagen Bioscience, Inc.'s last earnings report?
    • When does Niagen Bioscience, Inc. report earnings?

    What is the ticker symbol for Niagen Bioscience, Inc.?

    The ticker symbol for Niagen Bioscience, Inc. is NASDAQ:CDXC

    Does Niagen Bioscience, Inc. pay dividends?

    No, Niagen Bioscience, Inc. does not pay dividends

    What sector is Niagen Bioscience, Inc. in?

    Niagen Bioscience, Inc. is in the Healthcare sector

    What industry is Niagen Bioscience, Inc. in?

    Niagen Bioscience, Inc. is in the Biotechnology industry

    What country is Niagen Bioscience, Inc. based in?

    Niagen Bioscience, Inc. is headquartered in United States

    When did Niagen Bioscience, Inc. go public?

    Niagen Bioscience, Inc.'s initial public offering (IPO) was on June 25, 2008

    Is Niagen Bioscience, Inc. in the S&P 500?

    No, Niagen Bioscience, Inc. is not included in the S&P 500 index

    Is Niagen Bioscience, Inc. in the NASDAQ 100?

    No, Niagen Bioscience, Inc. is not included in the NASDAQ 100 index

    Is Niagen Bioscience, Inc. in the Dow Jones?

    No, Niagen Bioscience, Inc. is not included in the Dow Jones index

    When was Niagen Bioscience, Inc.'s last earnings report?

    Niagen Bioscience, Inc.'s most recent earnings report was on May 8, 2025

    When does Niagen Bioscience, Inc. report earnings?

    The date for Niagen Bioscience, Inc.'s next earnings report has not been announced yet
    On this page